GO:0005375 copper ion transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005375 (copper ion transmembrane transporter activity) is a molecular function that enables the transfer of copper (Cu) ions across a membrane.
• Copper transport is essential for cuproenzyme biogenesis, iron metabolism, and protection against copper toxicity.
• P-type copper ATPases (ATP7A, ATP7B) are the best-characterized copper ion transmembrane transporters and couple ATP hydrolysis to copper translocation.
• SLC31A1 (CTR1) mediates high-affinity copper uptake, while ATP7A/ATP7B drive efflux and Golgi loading.
• Defects in copper transport cause Wilson disease (ATP7B) and Menkes disease (ATP7A), and altered copper homeostasis is linked to diabetes, inflammation, and neurotoxicity.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are key tools for dissecting copper transporter function and therapeutic potential.
Description
Copper is an essential trace element that serves as a catalytic and structural cofactor in enzymes involved in respiration, iron homeostasis, antioxidant defense, and neurotransmitter synthesis. Because free copper can generate reactive oxygen species and disrupt cellular redox balance, organisms have evolved dedicated transport systems to move copper across membranes in a controlled manner. The Gene Ontology molecular function GO:0005375, copper ion transmembrane transporter activity, captures the core activity that enables copper ions to cross a lipid bilayer, a process fundamental to copper homeostasis in bacteria, plants, and animals. Understanding this activity is critical for researchers studying metal biology, inherited transport disorders, and emerging roles of copper in cancer and inflammation. At the molecular level, copper ion transmembrane transporter activity is executed by membrane proteins that couple copper movement to energy sources such as ATP hydrolysis or proton gradients. In eukaryotes, P-type ATPases of the ATP7A/ATP7B family are the principal copper-transporting ATPases, while SLC31A1 (CTR1) mediates copper uptake. In bacteria, a redox- and proton-coupled inner membrane transporter can import copper into the cytoplasm, illustrating the diversity of mechanisms that fall under this GO term. These transporters are not merely passive conduits; they are tightly regulated to avoid copper overload and to deliver copper to specific cuproproteins. For biomedical researchers, GO:0005375 provides a functional annotation that links genes, diseases, and experimental models. Mutations in ATP7B cause Wilson disease, a disorder of copper accumulation, and mutations in ATP7A cause Menkes disease, a copper-deficiency disorder. More recently, copper transport and cuproptosis have been implicated in inflammatory bowel disease, diabetes, and bortezomib-induced peripheral neurotoxicity. This article reviews the definition, mechanism, key genes, disease relevance, and research methods for copper ion transmembrane transporter activity, with a focus on how CRISPR-based models can accelerate discovery.
copper ion transmembrane transporter activity At A Glance
| GO ID | GO:0005375 |
|---|---|
| GO term | copper ion transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | copper uptake transmembrane transporter activity; intracellular copper ion transporter; plasma membrane copper transporter |
| Major function | Enables transfer of copper (Cu) ions across a membrane |
| Representative proteins | ATP7A, ATP7B, SLC31A1 (CTR1), bacterial copper importers |
| Cofactors/energy | ATP hydrolysis for P-type ATPases; proton gradient and redox coupling for some bacterial transporters |
| Disease links | Wilson disease, Menkes disease, diabetes, inflammatory bowel disease, neurotoxicity |
What Is GO:0005375?
GO:0005375, copper ion transmembrane transporter activity, is defined as the molecular function that enables the transfer of copper (Cu) ions from one side of a membrane to the other. This activity is distinct from copper binding or copper chaperone activity because it explicitly requires transmembrane movement. It includes transporters that mediate copper uptake, intracellular copper transport, and plasma membrane copper efflux.
Why Is copper ion transmembrane transporter activity Important in Cell Biology?
Copper ion transmembrane transporter activity is essential for life because copper is required for the function of key enzymes such as cytochrome c oxidase, superoxide dismutase, and ceruloplasmin, yet excess copper is toxic. Transporters maintain copper homeostasis by controlling uptake, distribution, and efflux, and their dysfunction leads to severe human disorders including Wilson and Menkes diseases. Moreover, copper transport is increasingly recognized as a modulator of inflammation, metabolic disease, and cancer therapy responses, making GO:0005375 a high-value annotation for both basic and translational research.
• Maintains cellular copper homeostasis and prevents copper toxicity.
• Supports cuproenzyme biogenesis, including cytochrome c oxidase and superoxide dismutase.
• Mutations in ATP7B cause Wilson disease, a copper overload disorder.
• Mutations in ATP7A cause Menkes disease, a copper deficiency disorder.
• Copper transport is linked to diabetes mellitus and metabolic dysregulation.
• Implicated in inflammatory bowel disease through intestinal epithelial copper toxicity.
• Contributes to bortezomib-induced peripheral neurotoxicity via ATF3/SLC31A1-mediated cuproptosis.
• Bacterial copper importers are potential antimicrobial targets.
• Copper transport influences acute pancreatitis through crosstalk with calcium and iron signals.
• Provides a functional annotation for CRISPR screens and drug discovery.
Molecular Mechanism of copper ion transmembrane transporter activity
Substrate recognition and copper binding
In simple terms: The transporter first grabs copper ions on one side of the membrane.
Copper ion transmembrane transporters contain specific metal-binding motifs, such as cysteine-rich domains in P-type ATPases, that coordinate Cu(I) with high affinity. In SLC31A1 (CTR1), methionine-rich motifs mediate copper uptake. These binding events ensure selectivity for copper over other divalent cations and initiate the transport cycle.
Energy coupling and conformational changes
In simple terms: The transporter uses energy to change shape and push copper across the membrane.
P-type copper ATPases (ATP7A, ATP7B) couple ATP hydrolysis to the phosphorylation of a conserved aspartate residue, driving conformational transitions that translocate copper across the membrane. In bacteria, a redox- and proton-coupled inner membrane transporter mediates copper import to the cytoplasm, using the proton motive force and redox state to drive uptake. These distinct energy-coupling mechanisms illustrate the diversity of copper transport strategies.
Intracellular copper delivery and efflux
In simple terms: Once inside, copper is handed off to other proteins or pumped out of the cell.
After transport, copper is delivered to copper chaperones and cuproenzymes, or is effluxed by ATP7A/ATP7B at the plasma membrane or loaded into the secretory pathway. In Wilson disease, impaired ATP7B function leads to copper accumulation in the liver and brain. In intestinal epithelial cells, copper toxicity can be promoted by glutaredoxin 1, highlighting the interplay between transport and redox regulation.
Regulation of transporter activity
In simple terms: Cells adjust copper transport based on need and stress.
Copper transporter expression and localization are regulated by copper availability, hormones, and stress pathways. For example, ATF3 regulates SLC31A1 in the context of bortezomib-induced neurotoxicity, linking stress signaling to copper uptake. In diabetes, altered copper homeostasis affects transport and cuproenzyme function. These regulatory layers ensure that copper is delivered when needed but does not accumulate to toxic levels.
Key Genes Involved in GO:0005375 copper ion transmembrane transporter activity
The following genes encode proteins that directly or indirectly contribute to copper ion transmembrane transporter activity and are commonly studied in this field.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ATP7A | P-type copper-transporting ATPase; mediates copper efflux and Golgi loading | Menkes disease; copper deficiency; CRISPR models for transport studies |
| ATP7B | P-type copper-transporting ATPase; biliary copper excretion | Wilson disease; copper overload; knockout and point-mutation models |
| SLC31A1 (CTR1) | High-affinity copper uptake transporter | Cuproptosis; neurotoxicity; cancer therapy |
| SLC31A2 (CTR2) | Copper transporter family member; modulates copper uptake | Copper homeostasis; potential cancer target |
| ATOX1 | Copper chaperone delivering copper to ATP7A/ATP7B | Copper trafficking; Wilson/Menkes modifier |
| CCS | Copper chaperone for SOD1 | Antioxidant defense; copper delivery |
| COX17 | Copper chaperone for cytochrome c oxidase | Mitochondrial copper transport |
| MT1A | Metallothionein; binds copper and zinc | Copper detoxification; inflammation |
| GLRX1 | Glutaredoxin 1; redox regulation | Intestinal copper toxicity in IBD |
| ATF3 | Stress-responsive transcription factor | Regulates SLC31A1 in neurotoxicity |
| CP | Ceruloplasmin; copper-containing ferroxidase | Iron and copper metabolism |
| SOD1 | Cu/Zn superoxide dismutase | Antioxidant defense; ALS |
| MT2A | Metallothionein 2A | Copper buffering; stress response |
| COMMD1 | Copper metabolism protein | Wilson disease modifier |
| XIAP | Inhibitor of apoptosis; copper-binding | Copper homeostasis and apoptosis |
| Bacterial CopA | P-type ATPase for copper efflux in bacteria | Antimicrobial target |
| Bacterial Ctr | Copper importer in bacteria | Redox- and proton-coupled copper import |
| P-type ATPase family | Evolutionarily conserved copper transporters | Comparative genomics and evolution |
How Is copper ion transmembrane transporter activity Regulated?
Copper ion transmembrane transporter activity is regulated at multiple levels. Copper availability itself modulates transporter trafficking and degradation; for example, ATP7A and ATP7B relocalize in response to intracellular copper levels. Transcriptional regulation occurs through stress-responsive factors such as ATF3, which can influence SLC31A1 expression in neurotoxicity models. In diabetes, hormonal and metabolic signals alter copper homeostasis and transporter function. Additionally, redox state and proton gradients regulate bacterial copper import, linking transport to cellular energetics. These regulatory mechanisms ensure that copper is delivered to cuproproteins while preventing toxic accumulation.
copper ion transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ATP7B | Wilson disease; copper overload | Knockout and point-mutation cell models; liver organoids |
| ATP7A | Menkes disease; copper deficiency | Knockout and knock-in models; neuronal cells |
| SLC31A1 | Cuproptosis; neurotoxicity | Overexpression and knockout in neuronal cells |
| GLRX1 | Inflammatory bowel disease; copper toxicity | Intestinal epithelial knockout models |
| ATF3 | Bortezomib-induced neurotoxicity | Knockout and overexpression in sensory neurons |
Wilson disease and Menkes disease
Wilson disease is caused by mutations in ATP7B, leading to impaired biliary copper excretion and copper accumulation in the liver, brain, and other organs. Menkes disease results from ATP7A mutations and causes systemic copper deficiency, affecting connective tissue and nervous system development. Both disorders underscore the critical role of copper ion transmembrane transporter activity in human health.
Diabetes mellitus and metabolic disease
Copper homeostasis is altered in diabetes mellitus, where changes in copper transport and cuproenzyme activity contribute to oxidative stress and metabolic dysfunction. Researchers study ATP7A, ATP7B, and SLC31A1 in models of insulin resistance and beta-cell function.
Inflammatory bowel disease and copper toxicity
In inflammatory bowel disease, glutaredoxin 1 promotes intestinal epithelial cell copper toxicity, implicating copper transport and redox regulation in mucosal damage. This highlights the need to understand how copper transporters modulate inflammation.
Neurotoxicity and cuproptosis
ATF3/SLC31A1-mediated cuproptosis contributes to bortezomib-induced peripheral neurotoxicity, and (-)-epigallocatechin gallate can intervene. This links copper uptake and cuproptosis to chemotherapy side effects and potential therapeutic strategies.
From copper ion transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ATP7B impair copper efflux? | ATP7B knockout cell line (e.g., HepG2) |
| Does a specific ATP7B mutation cause Wilson disease? | Point-mutation knock-in via CRISPR |
| Can tagged ATP7A be used to track trafficking? | Knock-in of fluorescent or epitope tag |
| Does SLC31A1 overexpression increase copper uptake? | Overexpression cell model |
| Does ATF3 regulate SLC31A1 in neurotoxicity? | ATF3 knockout and overexpression in neuronal cells |
| Can CRISPR library screening identify copper transport modulators? | Genome-wide CRISPR knockout library |
How to Study the copper ion transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of transporter function | ATP7B, ATP7A, SLC31A1 studies |
| Point-mutation knock-in | Effect of specific patient variants | Wilson disease modeling |
| Overexpression | Gain of copper transport activity | SLC31A1 uptake studies |
| Tagged knock-in | Protein localization and trafficking | ATP7A/ATP7B imaging |
| Fluorescent copper sensors | Intracellular copper levels | Live-cell transport assays |
| RNA-seq | Transcriptional changes | ATF3/SLC31A1 pathway analysis |
| Proteomics | Protein expression and interactions | Cuproptosis and redox studies |
| CRISPR library screening | Genome-wide modifiers of copper transport | Drug target discovery |
CRISPR knockout and point-mutation models
CRISPR-Cas9 knockout of ATP7B, ATP7A, or SLC31A1 allows researchers to test loss-of-function phenotypes in copper transport. Point-mutation knock-in can model specific patient variants, such as those in Wilson disease.
Overexpression and tagged knock-in
Overexpression of copper transporters enables gain-of-function studies, while tagged knock-in allows visualization of protein localization and trafficking. These approaches are useful for studying copper efflux and uptake dynamics.
Copper flux and imaging assays
Fluorescent copper sensors and radioisotope uptake assays measure copper transport activity in live cells. Imaging of tagged transporters reveals subcellular localization changes in response to copper.
Transcriptomics and proteomics
RNA-seq and proteomics can identify genes and pathways regulated by copper transporters, including ATF3/SLC31A1 axes. These methods help uncover downstream effects such as cuproptosis and oxidative stress.
How CRISPR Can Be Used to Study GO:0005375 copper ion transmembrane transporter activity
Knockout
CRISPR knockout of copper transporter genes such as ATP7B or SLC31A1 creates null cell models to study copper accumulation, efflux defects, and downstream phenotypes. These models are valuable for validating gene function in disease contexts.
Point Mutation
Point-mutation knock-in using CRISPR can replicate patient-specific mutations in ATP7B or ATP7A, enabling precise genotype-phenotype studies. This approach is essential for understanding missense variants of uncertain significance.
Knock-in
Knock-in of tags or reporters into endogenous loci allows real-time tracking of copper transporter localization and dynamics. This is particularly useful for studying ATP7A/ATP7B trafficking under different copper conditions.
Overexpression
CRISPR activation or cDNA overexpression can increase copper transporter levels to study gain-of-function effects, such as enhanced copper uptake by SLC31A1. Overexpression models help identify saturation and toxicity thresholds.
How EDITGENE Supports copper ion transmembrane transporter activity Research
Researchers studying copper ion transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in copper transport, disease progression, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for such studies.
Contact EDITGENE today to design your custom CRISPR model for copper ion transmembrane transporter activity research.
Frequently Asked Questions About copper ion transmembrane transporter activity
What is GO:0005375?
GO:0005375 is the Gene Ontology molecular function term for copper ion transmembrane transporter activity, which enables the transfer of copper ions across a membrane.
What genes are involved in copper ion transmembrane transporter activity?
Key genes include ATP7A, ATP7B, SLC31A1 (CTR1), and bacterial copper transporters.
What diseases are linked to copper transport?
Wilson disease, Menkes disease, diabetes, inflammatory bowel disease, and bortezomib-induced neurotoxicity.
How is copper ion transmembrane transporter activity regulated?
It is regulated by copper availability, stress-responsive transcription factors like ATF3, and redox/proton gradients in bacteria.
What is the difference between copper transport and copper chaperones?
Copper transporters move copper across membranes, while chaperones deliver copper to specific proteins within cells.
Which experimental models are used to study copper transport?
CRISPR knockout, point-mutation knock-in, overexpression, and tagged knock-in cell models.
What is cuproptosis and how does it relate to copper transport?
Cuproptosis is a copper-dependent cell death pathway linked to SLC31A1-mediated copper uptake.
Can CRISPR screens identify copper transport modulators?
Yes, genome-wide CRISPR screens can uncover genes that regulate copper transport and toxicity.
What is the role of ATP7B in Wilson disease?
ATP7B mutations impair biliary copper excretion, leading to copper accumulation in Wilson disease.
How does EDITGENE support copper transport research?
EDITGENE provides CRISPR knockout, point-mutation, knock-in, overexpression, library screening, and bioinformatics services.
Conclusion
Copper ion transmembrane transporter activity (GO:0005375) is a fundamental molecular function that maintains copper homeostasis and supports diverse physiological processes. Dysregulation of copper transport is implicated in severe diseases, including Wilson and Menkes diseases, diabetes, inflammatory bowel disease, and neurotoxicity. Advances in CRISPR-based models and screening technologies are accelerating the discovery of new mechanisms and therapeutic targets in copper biology.
References
- 1. Zhang T et al.. 2026. Glutaredoxin 1 promotes intestinal epithelial cell copper toxicity in inflammatory bowel disease.. Redox Biol 93:104164 PMID: 41985411
- 2. Lowe J et al.. 2017. Dissecting copper homeostasis in diabetes mellitus.. IUBMB Life 69(4):255-262 PMID: 28276155
- 3. Inesi G et al.. 2014. Biochemical characterization of P-type copper ATPases.. Biochem J 463(2):167-76 PMID: 25242165
- 4. Wang H et al.. 2024. Ion channels in acinar cells in acute pancreatitis: crosstalk of calcium, iron, and copper signals.. Front Immunol 15:1444272 PMID: 39606246
- 5. Palmer CD et al.. 2026. A redox- and proton-coupled inner membrane transporter mediates copper import to the bacterial cytoplasm.. Proc Natl Acad Sci U S A 123(21):e2601726123 PMID: 42154561
- 6. Wang Y et al.. 2026. ATF3/SLC31A1-Mediated Cuproptosis Contributes to Bortezomib-Induced Peripheral Neurotoxicity and Intervention by (-)-Epigallocatechin Gallate.. Int J Mol Sci 27(8) PMID: 42074318
- 7. Migocka M. 2015. Copper-transporting ATPases: The evolutionarily conserved machineries for balancing copper in living systems.. IUBMB Life 67(10):737-45 PMID: 26422816
- 8. Fatemi N et al.. 2002. Molecular mechanism of copper transport in Wilson disease.. Environ Health Perspect 110 Suppl 5(Suppl 5):695-8 PMID: 12426114
